SLC9A9: A Protein Target for Neurodegenerative Diseases (G285195)

Target Name: SLC9A9

NCBI ID: G285195

SLC9A9

SLC9A9: A Protein Target for Neurodegenerative Diseases

SLC9A9 (NHE9) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the NHE4 family of transmembrane proteins, which are characterized by the presence of a nucleotide- binding oligomerization (NBO) domain in their extracellular domain.

SLC9A9 is involved in a variety of physiological processes in the body, including cell signaling, neurotransmitter release, and inflammation. It has been implicated in the development and progression of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

Due to its involvement in these processes, SLC9A9 has become a promising drug target for a variety of neurodegenerative diseases. Studies have suggested that inhibiting SLC9A9 activity could be an effective way to treat these disorders.

One approach to inhibiting SLC9A9 activity is through the use of small molecules, such as drugs that bind to specific residues on the protein. These molecules can either inhibit SLC9A9 function directly or modulate the activity of other proteins that interact with SLC9A9.

Another approach to inhibiting SLC9A9 activity is through the use of antibodies, which are proteins that recognize and bind to specific epitopes (patches) on the protein. These antibodies can either bind to SLC9A9 directly or interact with other proteins that interact with SLC9A9.

SLC9A9 has also been targeted by researchers using technologies such as CRISPR/Cas9 to knockdown (reduce) the expression of the protein. This approach is useful for studying the function of SLC9A9 and its potential as a drug target.

In addition to its potential as a drug target, SLC9A9 is also a potential biomarker for certain neurological disorders. The presence of SLC9A9 in brain tissue has been reported in individuals with Alzheimer's disease, and its levels have been correlated with the severity of the disease.

Overall, SLC9A9 is a promising drug target and biomarker for the treatment of neurodegenerative diseases. Further research is needed to fully understand its function and potential as a therapeutic agent.

Protein Name: Solute Carrier Family 9 Member A9

Functions: Endosomal Na(+), K(+)/H(+) antiporter. Mediates the electroneutral exchange of endosomal luminal H(+) for a cytosolic Na(+) or K(+) (Probable). By facilitating proton efflux, SLC9A9 counteracts the acidity generated by vacuolar (V)-ATPase, thereby limiting luminal acidification. Regulates organellar pH and consequently, e.g., endosome maturation and endocytic trafficking of plasma membrane receptors and neurotransporters (PubMed:28130443, PubMed:15522866, PubMed:24065030). Promotes the recycling of transferrin receptors back to the cell surface to facilitate additional iron uptake in the brain (PubMed:28130443). Regulates synaptic transmission by regulating the luminal pH of axonal endosomes (By similarity). Regulates phagosome lumenal pH, thus affecting phagosome maturation, and consequently, microbicidal activity in macrophages (By similarity). Can also be active at the cell surface of specialized cells, e.g., in the inner ear hair bundles uses the high K(+) of the endolymph to regulate intracelular pH (By similarity)

The "SLC9A9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC9A9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets